posted on 2013-12-06, 00:00authored bySiobán D. Harlow, Margery Gass, Janet E. Hall, Roger Lobo, Pauline Maki, Robert W. Rebar, Sherry Sherman, Patrick M. Sluss, Tobie J. de Villiers
Objective: The aim of this article is to summarize the recommended updates to the 2001 Stages of Reproductive Aging Workshop (STRAW) criteria. The 2011 STRAW 10 reviewed advances in understanding of the critical changes in hypothalamic-pituitary-ovarian function that occur before and after the final menstrual period.
Methods: Scientists from five countries and multiple disciplines evaluated data from cohort studies of midlife women and in the context of chronic illness and endocrine disorders on change in menstrual, endocrine, and ovarian markers of reproductive aging including antimu¨ llerian hormone inhibin-B, follicle-stimulating hormone, and antral follicle count. Modifications were adopted by consensus.
Results: STRAW 10 simplified bleeding criteria for the early and late menopausal transition, recommended modifications to criteria for the late reproductive stage (Stage -3) and the early postmenopause stage (Stage 1), provided information on the duration of the late transition
(Stage -1) and early postmenopause (Stage 1), and recommended application regardless of women’s age, ethnicity, body size, or lifestyle characteristics.
Conclusions: STRAW 10 provides a more comprehensive basis for assessing reproductive aging in research and clinical contexts. Application of the STRAW 10 staging system should improve comparability of studies of midlife women and facilitate clinical decision making. Nonetheless, important knowledge gaps persist, and seven research priorities are identified. (J Clin Endocrinol Metab 97: 1159–1168, 2012)
Funding
Funding/support:
The Stages of Reproductive Aging Workshop (STRAW) 10
had grant support from the National Institutes of Health (NIH),
Department of Health and Human Services (DHHS), through
the National Institute on Aging (NIA) (AG039961), and the NIH
Office of Research on Women’s Health (ORWH) as well as from
The North American Menopause Society (NAMS), the American
Society for Reproductive Medicine (ASRM), the International
Menopause Society (IMS), and the Endocrine Society.